Scilex Holding (SCLXW) Operating Margin (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Operating Margin of 374.06% in Q1 2026, up 83.7% quarter-over-quarter from 2295.25% in Q4 2025, and up 18390.0% on a YoY basis from N/an in Q1 2025.
Scilex Holding (SCLXW) Operating Margin (2022 - 2026) Analysis & Trends
Scilex Holding's Operating Margin history runs 5 years deep, the most recent figure standing at 374.06% for Q1 2026.
- In Q1 2026, Operating Margin rose 18390.0% year-over-year to 374.06%; the TTM figure through Mar 2026 stood at 1033.39% (down 85232.0% YoY), while the FY2025 annual figure was 1141.94%, down 99457.0% from the prior year.
- Operating Margin was 374.06% for Q1 2026 at Scilex Holding, up from 2295.25% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 93.31% in Q3 2022 to a low of 2295.25% in Q4 2025.
- Historically, Operating Margin has averaged 428.13% across 5 years, with a median of 181.32% in 2023.
- The sharpest annual moves came in 2024 and 2025: Operating Margin soared 24559 bps in 2024, then tumbled 210479 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 165.63% in 2022, then gained by 18 bps to 136.23% in 2023, then tumbled by 40 bps to 190.46% in 2024, then tumbled by 1105 bps to 2295.25% in 2025, then soared by 84 bps to 374.06% in 2026.
- The last three Operating Margin figures came in at 374.06% (Q1 2026), 2295.25% (Q4 2025), and 1766.21% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.58% |
| 10 | Scilex Holding | - | - | 4.15 Mn | -374.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -374.06% |
| Dec 31, 2025 | -2,295.25% |
| Sep 30, 2025 | -1,766.21% |
| Jun 30, 2025 | -207.23% |
| Mar 31, 2025 | -557.96% |
| Dec 31, 2024 | -190.46% |
| Sep 30, 2024 | -137.97% |
| Jun 30, 2024 | -95.44% |
| Mar 31, 2024 | -178.96% |
| Dec 31, 2023 | -136.23% |
| Sep 30, 2023 | -383.56% |
| Jun 30, 2023 | -181.32% |
| Mar 31, 2023 | -240.72% |
| Dec 31, 2022 | -165.63% |
| Sep 30, 2022 | -93.31% |
| Jun 30, 2022 | -144.73% |
| Mar 31, 2022 | -129.27% |